期刊文献+

先天性心脏病并重度肺动脉高压患儿血浆偶联因子6变化的意义 被引量:5

Changes and significance of plasma coupling factor 6 in patients with congenital heart disease with severe pulmonary hypertension
原文传递
导出
摘要 目的研究血浆偶联因子6(CF6)在先天性心脏病(CHD)并重度肺动脉高压(PAH)患儿中的变化及意义。方法选取2014年1月至2015年1月在开封儿童医院就诊的CHD患儿155例,根据合并PAH情况将患儿分为3组:CHD未合并PAH患儿40例为无PAH组,CHD合并轻中度PAH患儿73例为轻中度PAH组,CHD合并重度PAH患儿42例为重度PAH组。采用放射免疫法对3组患儿血浆中CF6水平进行检测,分析CF6水平与PAH程度的相关性。结果无PAH组、轻中度PAH组、重度PAH组术前CF6水平分别为(189.6±43.2)ng/L、(169.5±87.1)ng/L、(303.1±80.5)ng/L,重度PAH组CF6水平较无PAH组、轻中度PAH组明显升高(P均〈0.01)。术后1d,重度PAH组血浆CF6水平与轻中度PAH组、无PAH组比较差异有统计学意义(P均〈0.05);术后3、7、14、28d,重度PAH组血浆CF6水平与无PAH组比较差异均有统计学意义(P均〈0.05)。重度PAH患儿肺动脉收缩压/血压收缩压比值与血浆CF6水平呈正相关(r=0.658,P〈0.01)。结论CHD合并PAH患儿血浆CF6水平升高,且升高水平与PAH程度呈正相关,提示其可能是重度PAH形成的重要因素之一,可将其作为治疗CHD合并重度PAH儿童的无创指标。
出处 《中华实用儿科临床杂志》 CSCD 北大核心 2016年第6期469-470,共2页 Chinese Journal of Applied Clinical Pediatrics
  • 相关文献

参考文献6

  • 1Schuuring M, Bouma B. Treatment of segmental pulmonary artery hyper- tension in adults with congenital heart disease[ J]. Int J Cardiol,2013, 164 ( 1 ) : 106 - 110. DOI : 10.1016/j. ijcard. 2011.06. 084.
  • 2Osanai T, Tanaka M, Magota K, et al. Coupling factor 6-induced activa- tion of ecto-F1 Fo complex induces insulin resistance, mild glucose into- lerance and elevated blood pressure in mice [ J ]. Diabetologia, 2012,55 (2) :520 - 529. DOI : 10. 1007/s00125-011-2341 -z.
  • 3无.肺动脉高压筛查诊断与治疗专家共识[J].中华心血管病杂志,2007,35(11):979-987. 被引量:271
  • 4Sharma V, Berkelhamer S, Lakshminrusimha S. Persistent pulmonary hy- pertension of the newborn [ J]. Mate Heal Neon Perinatol, 2015,155 (2) :20 -29. DOI:10.1186/s40748-015-0015-4.
  • 5Osanai T, Magota K, Okumura K. Coupling factor 6 as a novel vasoactive and proatherogenic peptide in vascular endothelial cells. [J].Naunyn Schmiedebergs Arch Pharmacol, 2009,380 ( 3 ) : 205 - 214. DOI : 10. 1007/s00210-009-0431 -y.
  • 6闫芳,刘艳兵,王军,张会军,吕瑛,李志杰.先天性心脏病合并肺动脉高压低体质量患儿血浆偶联因子6的含量及意义[J].河北医科大学学报,2013,34(12):1501-1503. 被引量:4

二级参考文献38

  • 1荆志成,徐希奇.肺动脉高压现代分类和诊断策略[J].中华心血管病杂志,2004,32(12):1160-1162. 被引量:40
  • 2胡盛寿,朱晓东,郭加强,吴学军,薛淦兴.先天性心脏病合并重度肺动脉高压的临床分级再讨论──314例远期疗效的随访研究[J].中国循环杂志,1995,10(3):151-154. 被引量:36
  • 3荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 4Proceeding of 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol, 2004,43(2 Suppl S) : 1S-90S.
  • 5Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 2004, 126( Suppl 1 ) : 1 S-92S.
  • 6Galie N, Torbicki A, Barst A, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J, 2004,25 ( 24 ) : 2243-2278.
  • 7Barst RJ, McGoon M, Torbicki A,et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 2004,43( 12 Suppl S) :40S-47S.
  • 8Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2004,43 (12) :5S-12S.
  • 9Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol, 2004,43(12 Suppl S) :25S-32S.
  • 10McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension : ACCP evidence-based clinical practice guidelines. Chest, 2004,126 (1 Suppl): 14S-34S.

共引文献273

同被引文献87

  • 1褚茂平,吴蓉洲,任跃,徐强,陈其,项如莲.先天性心脏病合并肺动脉高压患儿肺动脉肾上腺髓质素、内皮素1和一氧化氮浓度变化的临床意义探讨[J].中华儿科杂志,2007,45(10):779-780. 被引量:3
  • 2Nold-Petry CA, Rudloff I,Baumer Y,et al. IL-32 promotes angiogen-esis[ J]. J Immunol,2014,192(2) :589-602. DOI: 10. 4049/jimmu-nol. 1202802.
  • 3Jiang Y,Nohe A, Bragdon B,et al. Trapping of BMP receptors indistinct membrane domains inhibits their function in pulmonary arte-rial hypertension [ J ]. Am J Physiol Lung Cell Mol Physiol,2011,301(2) : L218-227. DOI: http://dx. DOI. org/10. 1152/ajplung.00300.2010.
  • 4Zhao M,Austin ED,Hemnes AR,et al. An evidence-based knowl-edgebase of pulmonary arterial hypertension to identify genes andpathways relevant to pathogenesis[ J]. Mol Biosyst,2014,10(4):732-740. DOI: 0.1039/c3mb70496c.
  • 5Van Wijk B,Moorman AF, Van Den Hoff MJ. Role of bone mor-phogenetic proteins in cardiac differentiation [ J]. Cardiovasc Res,2007,74(2) :244-255. DOI: 10.1016/j. cardiores. 2006.11.022.
  • 6Kishigami S,Mishina Y. BMP signaling and early embryonic pat-terning [J]. Cytokine Growth Factor Rev, 2005,16 (3) : 265-278.DOI: 10.1016/j. cytogfr. 2005.04.002.
  • 7Miyazono K,Kamiya Y,Morikawa M. Bone morphogenetic proteinreceptors and signal transduction[ J]. J Biochem,2010,147 (1):35-51. DOI: 10.1093/jb/mvpl48.
  • 8Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bonemorphogenetic protein receptor-2 signaling promotes pulmonary arte-rial endothelial cell survival : implications for loss-of-function muta-tions in the pathogenesis of pulmonary hypertension [ J ]. Circ Res,2006,98(2) :209-217.D01:10.1161/01.RES.0000200180.01710.e6.
  • 9Wei ZQ,Salmon RM,Upton PD,et al. Regulation of bone morpho-genetic protein 9(BMP9)by redox-dependent proteolysis[ J]. J BiolChem,2014,289 (45 ) : 31150-31159. DOI: 10. 1074/jbc. Ml 14.579771.
  • 10Lafyatis R. Transforming growth factor beta~at the centre of system-ic sclerosis[ J]. Nat Rev Rheumatol,2014,10(12) :706-719. DOI:10.1038/nrrheum. 2014.137.

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部